<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609920</url>
  </required_header>
  <id_info>
    <org_study_id>12-2-032</org_study_id>
    <nct_id>NCT01609920</nct_id>
  </id_info>
  <brief_title>Nodal Staging in Breast Cancer With MRL</brief_title>
  <official_title>Non-invasive Nodal Staging in Breast Cancer With Magnetic Resonance Imaging Lymphography Using Gadofosveset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the diagnostic performance of gadofosveset enhanced
      magnetic resonance imaging lymphography (MRL).

      The diagnostic performance of MRL will be determined on the basis of a node-to-node matching
      of imaged nodes to the definitive histopathology. The pathologic examination of the sentinel
      lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) will be regarded as the
      golden standard for nodal involvement.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Manufacturer recently halted production of gadofosveset.
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The diagnostic performance (sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV)) of axillary MRL in predicting the involvement of metastases</measure>
    <time_frame>Participants will be followed from the moment of first out-hospital clinic vistit untill final breast surgery, an expected average of 4 weeks.</time_frame>
    <description>The main study parameter will be the diagnostic performace (sensitivity, specificity, NPV and PPV) of the axillary MRL in predicting the involvement of metastases in the investigated lymph nodes. Each node will be scored on MRL as 0= benign, 1=malign. These results will be compared with the histopathological results of the SNLB procedure of ALND procedure on an node by node basis. So the diagnostic performace can be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Gadofosveset MRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadofosveset enhanced MRL of axillary lymph nodes</intervention_name>
    <description>A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.</description>
    <arm_group_label>Gadofosveset MRL</arm_group_label>
    <other_name>Vasovist</other_name>
    <other_name>Ablavar</other_name>
    <other_name>Gadofosveset</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patient with histopathologically confirmed breast cancer about to undergo nodal
             staging.

          2. Willing and able to undergo all study procedures

          3. Has personally provided written informed consent.

        Exclusion Criteria:

          1. Age &lt;18,

          2. Pregnancy

          3. Contra indications for MRL such as pacemaker, aneurysm clips or severe claustrophobia.

          4. Allergy to any of the ingredients of Gadofosveset (Vasovist® /Ablavar®)

          5. Being unable to give informed consent in person

          6. Acute or chronic severe renal insufficiency (glomerular filtration rate &lt;45
             mL/min/1.73m2)1.

          7. Acute renal insufficiency of any severity due to the hepato-renal syndrome.

          8. Known (or suspicion of) QT- prolongation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R.G.H. Beets-Tan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center (MUMC) AZM</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6225 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>lymph node metastases</keyword>
  <keyword>breast cancer</keyword>
  <keyword>gadofosveset</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

